Related Experiment Video
Updated: May 23, 2025
07:30
Electromagnetic Navigation Transthoracic Nodule Localization for Minimally Invasive Thoracic Surgery
Published on: May 4, 2022
3.3K
Theranostics in Lung Neuroendocrine Tumors
Indraja D Dev1, Ameya D Puranik2, Nikolaos A Trikalinos3
1Department of Nuclear Medicine and Molecular Imaging, Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Center, Homi Bhabha National Institute, Navi Mumbai, Maharashtra, India.
Seminars in Nuclear Medicine
|March 7, 2025
Summary
Radiopharmaceutical therapy (Theranostics) offers precise treatment for lung neuroendocrine tumors (LNETs) by targeting somatostatin receptors. This review examines current Theranostics evidence and future strategies for managing LNETs.
Area of Science:
- Oncology
- Nuclear Medicine
- Radiopharmaceutical Therapy
Background:
- Neuroendocrine tumor incidence has risen due to better diagnostics.
- Lung neuroendocrine tumors (LNETs) require specific diagnostic and therapeutic approaches.
- Somatostatin receptors (SSTR) are key targets in neuroendocrine tumors.
Purpose of the Study:
- To review established evidence for Theranostics in LNET management.
- To highlight emerging diagnostic and therapeutic targets for LNETs.
Main Methods:
- Review of current literature on radiopharmaceutical therapy for LNETs.
- Analysis of SSTR-targeted agents for diagnosis and treatment.
- Exploration of novel therapeutic targets in LNETs.
Main Results:
- Theranostics, utilizing SSTR-targeting radiopharmaceuticals, has improved LNET management.
- Established evidence supports the role of Theranostics in precise LNET treatment with minimal side effects.
- Newer targets show promise for addressing complex LNET biology.
Conclusions:
- Theranostics represents a significant advancement in LNET management.
- Further research into novel targets is crucial for optimizing LNET treatment strategies.
- Personalized medicine approaches are key to managing rare and complex LNETs.
